drug trial

Bangalore, March 1: Amicus Therapeutics Inc. (NSDQ: AMCS), has come under the spotlight after it had to put a halt on the mid-stage trial of its new treatment for an uncommon muscle disorder.

This incident has seriously affected the company’s shares as they tumbled to an all time low of 34 percent. The company’s stock was among the top intraday losers on NASDAQ.

Lazard Capital Markets analyst Matthew Osborne, who was confident about the other two mid-stage studies, was quoted as saying, “It was a surprise to see these adverse events, but there is still an opportunity to demonstrate safety and activity for other diseases.”